PL2075007T3 - Leczenie choroby Alzheimera - Google Patents

Leczenie choroby Alzheimera

Info

Publication number
PL2075007T3
PL2075007T3 PL08170222T PL08170222T PL2075007T3 PL 2075007 T3 PL2075007 T3 PL 2075007T3 PL 08170222 T PL08170222 T PL 08170222T PL 08170222 T PL08170222 T PL 08170222T PL 2075007 T3 PL2075007 T3 PL 2075007T3
Authority
PL
Poland
Prior art keywords
disease
alzheimer
treatment
medicament
preparation
Prior art date
Application number
PL08170222T
Other languages
English (en)
Polish (pl)
Inventor
Barrio Manuel Sarasa
Original Assignee
Araclon Biotech Sl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Araclon Biotech Sl filed Critical Araclon Biotech Sl
Publication of PL2075007T3 publication Critical patent/PL2075007T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
PL08170222T 2003-05-08 2004-05-03 Leczenie choroby Alzheimera PL2075007T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ES200301054A ES2246105B1 (es) 2003-05-08 2003-05-08 Uso de anticuerpos para el tratamiento de enfermedades amiloideas.
EP04730882A EP1623719B1 (en) 2003-05-08 2004-05-03 Treatment of alzheimer's disease and cerebral amyloid angiopathy
EP08170222.7A EP2075007B9 (en) 2003-05-08 2004-05-03 Treatment for Alzheimer's disease

Publications (1)

Publication Number Publication Date
PL2075007T3 true PL2075007T3 (pl) 2013-09-30

Family

ID=32982086

Family Applications (3)

Application Number Title Priority Date Filing Date
PL04730882T PL1623719T3 (pl) 2003-05-08 2004-05-03 Leczenie choroby Alzheimer´a i mózgowej angiopatii amyloidowej
PL10012342T PL2356996T3 (pl) 2003-05-08 2004-05-03 Leczenie choroby Alzheimera
PL08170222T PL2075007T3 (pl) 2003-05-08 2004-05-03 Leczenie choroby Alzheimera

Family Applications Before (2)

Application Number Title Priority Date Filing Date
PL04730882T PL1623719T3 (pl) 2003-05-08 2004-05-03 Leczenie choroby Alzheimer´a i mózgowej angiopatii amyloidowej
PL10012342T PL2356996T3 (pl) 2003-05-08 2004-05-03 Leczenie choroby Alzheimera

Country Status (19)

Country Link
US (6) US20090162362A1 (es)
EP (5) EP2082747A3 (es)
JP (5) JP2006525288A (es)
CN (2) CN1784240A (es)
AT (1) ATE435024T1 (es)
AU (2) AU2004237373A1 (es)
BR (1) BRPI0410684A (es)
CA (1) CA2524571C (es)
CY (1) CY1109454T1 (es)
DE (1) DE602004021797D1 (es)
DK (3) DK1623719T3 (es)
ES (6) ES2246177B1 (es)
IL (8) IL171651A (es)
MX (1) MXPA05010914A (es)
PL (3) PL1623719T3 (es)
PT (3) PT2075007E (es)
RU (2) RU2385161C2 (es)
SI (1) SI1623719T1 (es)
WO (1) WO2004098631A1 (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
ES2246177B1 (es) * 2003-05-08 2007-03-01 Universidad De Zaragoza. Uso de anticuerpos para el tratamiento de enfermedades amiloideas.
TWI355389B (en) 2004-07-30 2012-01-01 Rinat Neuroscience Corp Antibodies directed against amyloid-beta peptide a
MY148086A (en) 2005-04-29 2013-02-28 Rinat Neuroscience Corp Antibodies directed against amyloid-beta peptide and methods using same
PL1954718T3 (pl) 2005-11-30 2015-04-30 Abbvie Inc Przeciwciała skierowane przeciwko A globulomerowi, ich reszty wiążące antygeny, odpowiednie hybrydomy, kwasy nukleinowe, wektory, komórki gospodarze, sposoby wytwarzania tych przeciwciał, kompozycje zawierające te przeciwciała, zastosowania tych przeciwciał i sposoby stosowania tych przeciwciał
US8497072B2 (en) 2005-11-30 2013-07-30 Abbott Laboratories Amyloid-beta globulomer antibodies
PL2361638T3 (pl) * 2005-12-12 2014-08-29 Ac Immune Sa Przeciwciała monoklonalne swoiste wobec A beta 1-42 o właściwościach terapeutycznych
AU2007275467B2 (en) 2006-07-14 2013-12-05 Ac Immune S.A. Humanized antibody against amyloid beta
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
EP2486928A1 (en) 2007-02-27 2012-08-15 Abbott GmbH & Co. KG Method for the treatment of amyloidoses
KR20090115951A (ko) 2007-03-01 2009-11-10 프로비오드룩 아게 글루타미닐 사이클라제 저해제의 신규 용도
US9656991B2 (en) 2007-04-18 2017-05-23 Probiodrug Ag Inhibitors of glutaminyl cyclase
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US9403902B2 (en) * 2007-10-05 2016-08-02 Ac Immune S.A. Methods of treating ocular disease associated with amyloid-beta-related pathology using an anti-amyloid-beta antibody
SG178809A1 (en) * 2007-10-05 2012-03-29 Genentech Inc Use of anti-amyloid beta antibody in ocular diseases
EP2149380A1 (en) * 2008-07-29 2010-02-03 Medivet Pharma, S.L. Veterinary immunotherapy compositions for the Aged Related Cognitive Dysfunction.
EP2258398A1 (en) * 2009-05-26 2010-12-08 Araclón Biotech, S. L. Albumin-amyloid peptide conjugates and uses thereof
CN102695546B (zh) 2009-09-11 2014-09-10 前体生物药物股份公司 作为谷氨酰胺酰环化酶抑制剂的杂环衍生物
CN102713633B (zh) 2009-12-11 2015-03-11 艾拉科隆生物技术公司 用于β-淀粉样肽的改进检测的方法和试剂
ES2586231T3 (es) 2010-03-03 2016-10-13 Probiodrug Ag Inhibidores de glutaminil ciclasa
DK2545047T3 (da) 2010-03-10 2014-07-28 Probiodrug Ag Heterocycliske inhibitorer af glutaminylcyclase (QC, EC 2.3.2.5)
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
WO2011131748A2 (en) 2010-04-21 2011-10-27 Probiodrug Ag Novel inhibitors
AU2011279221B2 (en) * 2010-07-14 2015-06-11 Merck Sharp & Dohme Corp. Anti-ADDL monoclonal antibody and uses thereof
BR112013002297A2 (pt) * 2010-07-30 2016-05-24 Ac Immune Sa anticorpos humanizados seguros e funcionais
WO2012024187A1 (en) 2010-08-14 2012-02-23 Abbott Laboratories Amyloid-beta binding proteins
EP2686313B1 (en) 2011-03-16 2016-02-03 Probiodrug AG Benzimidazole derivatives as inhibitors of glutaminyl cyclase
US10195257B2 (en) 2013-07-28 2019-02-05 Qantu Therapeutics, Inc. Vaccine formulations comprising quillaja desacylsaponins and beta amyloid peptides or tau protein to induce a Th2 immune response
ES2571055B1 (es) * 2016-02-15 2016-12-28 Araclon Biotech, S.L. Conjugado amiloide y usos y procedimientos del mismo
PL3461819T3 (pl) 2017-09-29 2020-11-30 Probiodrug Ag Inhibitory cyklazy glutaminylowej
PL237739B1 (pl) 2018-06-06 2021-05-17 Univ Gdanski Genisteina do zastosowania do leczenia choroby Alzheimera

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1339014C (en) * 1987-10-08 1997-03-25 Ronald E. Majocha Antibodies to a4 amyloid peptide
AU5525090A (en) * 1989-04-14 1990-11-16 Research Foundation For Mental Hygiene, Inc. Monoclonal antibody to amyloid peptide
ATE153534T1 (de) 1990-04-27 1997-06-15 John Mcmichael Verfahren und zusammensetzung zur behandlung von erkrankungen des zns hervorgerufen durch abnormales beta-amyloid-protein
US7427392B1 (en) * 1994-11-14 2008-09-23 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau
US8173127B2 (en) * 1997-04-09 2012-05-08 Intellect Neurosciences, Inc. Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof
US6743427B1 (en) * 1997-12-02 2004-06-01 Neuralab Limited Prevention and treatment of amyloidogenic disease
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7964192B1 (en) * 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
JP3980833B2 (ja) * 1998-08-20 2007-09-26 リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア βアミロイド斑及び神経原線維変化の標識方法
UA81216C2 (en) * 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
US20070128191A1 (en) * 2001-12-26 2007-06-07 Universidad De Zaragoza Polyclonal antibodies, preparation method thereof and use of same
EP1371986A1 (en) * 2002-06-06 2003-12-17 ABETA GmbH Diagnosis of Alzheimer's disease based on the hAbeta42:hAbeta40 ratio
WO2004013172A2 (en) * 2002-07-24 2004-02-12 Innogenetics N.V. Fragments of beta-amyloid as targets for vaccination against alzheimer disease
ES2201929B1 (es) * 2002-09-12 2005-05-16 Araclon Biotech, S.L. Anticuerpos policlonales, metodo de preparacion y uso de los mismos.
AU2003279216A1 (en) * 2002-10-09 2004-05-04 Rinat Neuroscience Corp. Methods of treating alzheimer's disease using antibodies directed against amyloid beta peptide and compositions thereof
RU2390350C2 (ru) * 2003-02-01 2010-05-27 Ньюралаб Лимитед Активная иммунизация для создания антител к растворимому а-бета
ES2246177B1 (es) * 2003-05-08 2007-03-01 Universidad De Zaragoza. Uso de anticuerpos para el tratamiento de enfermedades amiloideas.

Also Published As

Publication number Publication date
JP2006525288A (ja) 2006-11-09
US20210214394A1 (en) 2021-07-15
IL207875A0 (en) 2011-07-31
DK1623719T3 (da) 2009-11-09
DK2356996T3 (da) 2013-07-22
JP2018119011A (ja) 2018-08-02
ES2246105B1 (es) 2007-03-01
ES2423590T3 (es) 2013-09-23
BRPI0410684A (pt) 2006-06-20
CN1784240A (zh) 2006-06-07
ES2246177A1 (es) 2006-02-01
CA2524571C (en) 2017-01-10
EP2356996B9 (en) 2013-08-28
EP2075007A3 (en) 2009-11-11
US20170260234A1 (en) 2017-09-14
ES2423281T3 (es) 2013-09-19
EP2075007A2 (en) 2009-07-01
RU2526155C2 (ru) 2014-08-20
EP2356996A1 (en) 2011-08-17
ATE435024T1 (de) 2009-07-15
CN101264326A (zh) 2008-09-17
ES2246105A1 (es) 2006-02-01
ES2329369T3 (es) 2009-11-25
CY1109454T1 (el) 2014-08-13
RU2385161C2 (ru) 2010-03-27
SI1623719T1 (sl) 2009-12-31
IL207876A0 (en) 2011-07-31
PL1623719T3 (pl) 2010-11-30
US20140044725A1 (en) 2014-02-13
AU2011200170C1 (en) 2012-03-22
EP2082747A3 (en) 2010-01-13
EP2082747A2 (en) 2009-07-29
AU2011200170A1 (en) 2011-02-03
RU2009148539A (ru) 2011-06-27
US20090162362A1 (en) 2009-06-25
CA2524571A1 (en) 2004-11-18
DK2356996T5 (da) 2013-08-26
PL2356996T3 (pl) 2013-09-30
JP2016065100A (ja) 2016-04-28
RU2005134351A (ru) 2006-04-27
JP2012006967A (ja) 2012-01-12
US20200140488A1 (en) 2020-05-07
DE602004021797D1 (de) 2009-08-13
EP2075007B1 (en) 2013-05-22
PT2356996E (pt) 2013-08-23
IL207877A0 (en) 2011-07-31
AU2011200170B2 (en) 2011-09-01
IL207878A (en) 2013-02-28
MXPA05010914A (es) 2006-03-21
IL207880A (en) 2013-02-28
IL207879A (en) 2013-02-28
DK2075007T3 (da) 2013-07-29
JP2014129389A (ja) 2014-07-10
IL207881A0 (en) 2011-07-31
IL207875A (en) 2013-02-28
IL207880A0 (en) 2011-07-31
AU2004237373A1 (en) 2004-11-18
EP2305286A3 (en) 2011-11-09
EP2356996B1 (en) 2013-06-26
PT1623719E (pt) 2009-10-08
EP1623719B1 (en) 2009-07-01
WO2004098631A1 (es) 2004-11-18
EP1623719A1 (en) 2006-02-08
ES2246178A1 (es) 2006-02-01
ES2246177B1 (es) 2007-03-01
IL207877A (en) 2013-03-24
US20110262458A1 (en) 2011-10-27
IL207881A (en) 2013-02-28
EP2305286A2 (en) 2011-04-06
IL207876A (en) 2013-03-24
IL207878A0 (en) 2011-07-31
IL207879A0 (en) 2011-07-31
EP2075007B9 (en) 2013-09-04
ES2246178B1 (es) 2007-03-01
PT2075007E (pt) 2013-08-23
IL171651A (en) 2011-11-30

Similar Documents

Publication Publication Date Title
PL2356996T3 (pl) Leczenie choroby Alzheimera
ATE369380T1 (de) Impfstoff zur verhütung und behanldung von alzheimer-demenz und von amyloid-bezogenen krankheiten
ATE479442T1 (de) Beta-amyloidpeptid erkennende humanisierte antikörper
IS2925B (is) Ákvörðun á batahorfum sjúklings sem undirgengst meðhöndlun við Alzheimer-sjúkdómi
EA200602015A1 (ru) Гуманизированные антитела, распознающие бета-амилоидный пептид
EA200501891A1 (ru) Гуманизированные антитела, распознающие бета-амилоидный пептид
WO2002074240A3 (en) Anti-amyloid antibody based diagnosis and treatment of a neurological disease or disorder
EA200501560A1 (ru) Предотвращение и терапия амилоидогенной болезни
DK2380583T3 (da) Små peptider til behandling af Alzheimers sygdom og andre beta-amyloidprotein-fibrillogeneseforstyrrelser
WO2005012330A3 (en) AMYLOID β-PEPTIDE AND METHODS OF USE